health & science•Fri, August 21, 2026•4 min read

Moderna and Merck’s mRNA Cancer Vaccine Succeeds in Landmark Phase 3 Trial

In a historic breakthrough, a personalized mRNA cancer vaccine developed by Moderna and Merck has successfully met primary goals in a late-stage clinical trial. The treatment, when paired with immunotherapy, significantly reduced the risk of melanoma recurrence and spread. This result marks the first positive Phase 3 outcome for an mRNA-based personalized cancer therapy.

A New Era for Personalized Oncology

Medical history is being written as Moderna and Merck announce positive results from their Phase 3 clinical trial, INTerpath-001. The study evaluated an experimental, personalized mRNA cancer vaccine, known as intismeran, in combination with Merck’s established immunotherapy drug, Keytruda. The combination was tested on patients with surgically removed Stage IIB–IV melanoma, focusing on preventing the disease from returning or metastasizing.

The Results: Reducing Recurrence and Metastasis

The trial, which enrolled 1,137 high-risk patients, hit its primary target of Recurrence-Free Survival (RFS) and its secondary goal of Distant Metastasis-Free Survival (DMFS). For patients who have undergone surgery to remove their melanoma, preventing the disease from returning is the greatest challenge. By utilizing an mRNA platform—similar to the technology used in COVID-19 vaccines—the treatment is designed to train the immune system to identify and attack specific neoantigens unique to an individual's tumor.

First positive Phase 3 trial for a personalized mRNA-based cancer therapy.
Treatment combined with Keytruda outperformed standard immunotherapy alone.
Targeted patients with resected Stage IIB through IV melanoma.
No new safety signals were reported during the trial.

Why This Matters for Future Cancer Care

While the study is ongoing, the data provides a strong signal that personalized 'neoantigen' vaccines are a viable path forward for oncology. Rather than a one-size-fits-all drug, these vaccines are tailored to the patient, marking a shift toward more precise, adaptive medicine. The success of the INTerpath-001 trial could validate the broader INTerpath clinical development program, which is currently investigating the potential of intismeran across other tumor types, including lung, bladder, and renal cell cancers.

The results could herald a new, powerful approach in oncology, transforming survival and quality of life for patients.
— Clinical Science Industry Analysis

Key Takeaways

Moderna and Merck reported success in the INTerpath-001 Phase 3 trial for melanoma.
The experimental vaccine, intismeran, was used in combination with Keytruda.
The treatment significantly improved Recurrence-Free and Distant Metastasis-Free survival rates.
This is the first mRNA-based cancer therapy to succeed in a randomized Phase 3 study.
The companies are expanding research into other cancer types including lung and bladder cancer.

FAQ

What is the name of the new melanoma vaccine?

The experimental personalized mRNA vaccine is called intismeran.

How does the vaccine work?

It is a personalized 'neoantigen' vaccine designed to train the patient's immune system to recognize and fight specific proteins found in their unique tumor.

Was the vaccine used alone or with other drugs?

The vaccine was administered in combination with Merck’s immunotherapy drug, Keytruda.

Who is eligible for this treatment based on the trial?

The trial focused on high-risk patients with surgically removed (resected) Stage IIB–IV melanoma.

Is this the first successful Phase 3 trial for this type of vaccine?

Yes, this marks the first positive Phase 3 trial for an mRNA-based personalized cancer therapy.